B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 173.15 DKK 2.09% Market Closed
Market Cap: 13.7B DKK

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 203.89 DKK. Compared to the current market price of 173.15 DKK, Bavarian Nordic A/S is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
203.89 DKK
Undervaluation 15%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
80
vs Industry
76
Median 3Y
2.5
Median 5Y
4.8
Industry
7.3
Forward
2.1
vs History
50
vs Industry
9
Median 3Y
11.2
Median 5Y
10.2
Industry
23.3
Forward
9.8
vs History
34
vs Industry
14
Median 3Y
10.6
Median 5Y
10.6
Industry
19.8
vs History
vs Industry
3
Median 3Y
-8.4
Median 5Y
-12.3
Industry
22.6
vs History
92
vs Industry
58
Median 3Y
1.4
Median 5Y
1.9
Industry
2.7
vs History
80
vs Industry
68
Median 3Y
2.2
Median 5Y
4.7
Industry
7.6
Forward
1.9
vs History
73
vs Industry
62
Median 3Y
4.1
Median 5Y
8.6
Industry
9.4
vs History
58
vs Industry
13
Median 3Y
6.2
Median 5Y
7.6
Industry
4.7
Forward
5.9
vs History
44
vs Industry
10
Median 3Y
9
Median 5Y
8.4
Industry
4.8
Forward
8.3
vs History
36
vs Industry
15
Median 3Y
9.2
Median 5Y
9.3
Industry
5.3
vs History
vs Industry
3
Median 3Y
-11.1
Median 5Y
-11.7
Industry
3.8
vs History
80
vs Industry
57
Median 3Y
1.2
Median 5Y
1.5
Industry
5

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
13.5B DKK 2.2 10.2 6.2 9.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 651 194.5 -159 939.1 -194 217.1 -192 000.9
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 093.5 -534.2 -581.7 -566.2
AU
CSL Ltd
ASX:CSL
117.5B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 059 396.7
2.2
0%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 651 194.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 093.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.4
29%
0.6
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 30.4
10.2
0%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 939.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.2 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 14.4
6.2
4%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 217.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 18.7
9.3
8%
1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 000.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A